London, Thursday, 21st January, 2016 - IMImobile, which helps companies to engage with their customers via mobile technologies, has teamed up with BBC Media Action, with support from the Bill & Melinda Gates Foundation, to roll out free mobile health education services for the Government of India’s Ministry of Health and Family Welfare to nearly 10 million families and one million community health workers across India.
Union Minister for Health and Family Welfare, JP Nadda, recently launched a program to roll out two mobile health services developed by BBC Media Action and powered by IMImobile’s technology nationwide. These m-health services use the IMIconnect communications technology platform to make pre-recorded audio health messages available to millions of women. The services will educate families about simple steps that new and expectant mothers can take to improve their health, and the health of their children:
Mobile Academy service is a voice based mobile training course on reproductive, maternal, new-born and child health for Community Health workers, designed to expand their knowledge of life-saving preventative healthcare and enhance their capacity to engage effectively with families. Front-line workers can access the course from any phone and complete it at their convenience.Kilkari service is an IVR subscription service that delivers time-sensitive audio information about maternal and child health to the mobile phones of husbands, their pregnant wives, and young children for up to 72 weeks. The information is linked to the woman’s stage of pregnancy and/or child’s age.The services are currently being launched in Jharkhand, Madhya Pradesh, Orissa, Rajasthan, and Uttar Pradesh, and are already targeting 850,000 families every week.
Jay Patel, CEO, IMImobile, commented:
“We are delighted to support the launch of these vital services to improve front line health communication in areas where mobile communication is the only viable option for providing much needed health advice. This key initiative highlights how the use of mobile engagement technologies can make a huge difference to people’s lives.
“There are over one billion mobile users in India and we hope to play a crucial role in assisting organizations that need scalable multi-channel technologies in order to realise the vision of a Digital India.”
Rahul Mullick, Head of ICT & Supply Chain at the Bill and Melinda Gates Foundation, said:
“The national launch of mHealth services is a great step towards leveraging India’s increasing mobile penetration to make healthcare services accessible to everyone across India. We at the foundation believe technology can offer compelling solutions in solving public health challenges and are committed to supporting the government in its ambitious agenda of prioritising equitable access to public health services.”
Sara Chamberlain, Digital Director, BBC Media Action India, added:
“The Ministry of Health and Family Welfare’s commitment to using mobile phone technology to provide free reproductive, maternal, neo-natal and child health education to every new and expecting mother in India is a ground breaking step towards realizing the vision of Digital India. We are proud to be a part of this transformational initiative.”
-ENDS-
Enquiries:
IMImobile
Matthew Hooper / Alex Klose via Redleaf
Redleaf Communications
Charlie Geller
Helena Shadbolt
020 7382 4730
IMImobile@redleafpr.com
Notes to Editors:
The IMImobile Voice Application is integrated with an application called MOTECH, developed by Grammene Foundation for both inbound as well as outbound services.
IMImobile enables organisations of all sizes and sectors to maximise the potential of mobile technologies to improve customer engagement. We believe that mobile will sit at the heart of customer engagement strategies for years to come.
By removing the barriers and complexities to create and deploy mobile-led customer engagement solutions as part of a multi-channel framework, we provide software and services that helps organisations to improve customer experience, simplify business processes and enhance operational efficiency.
Our products and solutions built upon the IMIcloud act as an intelligent layer between existing IT systems and business processes to create, manage and launch services across mobile, digital and social communication channels.
Organisations that trust us to deliver smarter customer engagement include Vodafone, O2, Telefonica, Aircel, Airtel, EE, BSNL, AT&T, MTN, France Telecom, Centrica, Coca-Cola, Universal Music, Tata, the AA, the BBC and major financial institutions.
IMImobile is headquartered in London with offices in Hyderabad, Atlanta and Dubai and has 700 employees worldwide. IMImobile is quoted on the London Stock Exchange’s AIM market with the TIDM code IMO.
Source: RealWire
Gerrards Cross (United Kingdom) | Madrid (Spain), 18th February 2016 – People Who (www.peoplewho.co.uk), the European online platform for e-patients, is kicking off 2016 with the launch of its latest illness: atrial fibrillation. In collaboration with Daiichi Sankyo, the digital platform is launching a new space to spread awareness of the illness in the UK and to offer online services to help improve the lives of people affected by atrial fibrillation in any way, whether diagnosed themselves, caring for someone with the illness or just interested in finding out more.
Atrial fibrillation
Atrial fibrillation is a common heart rhythm disorder which affects 33.5 million people worldwide: nearly 0.5% of the world’s population[1]. What’s more, here in the UK it affects at least 1 million people, with many more thought to be living with the illness undiagnosed. And while many live with the illness without even realising it, it can lead to serious complications like stroke. But with the right treatment, it’s possible to live well with atrial fibrillation. Raising awareness of the illness is essential to ensure that patients get diagnosed as early as possible, helping them to live better with the illness and avoid its complications.
Atrial fibrillation affects different people in different ways. Some will notice symptoms like palpitations or shortness of breath, whilst in other cases it goes without symptoms. But given that it can lead to serious complications like stroke, it’s essential to be on the lookout. The surest way to identify it as soon as possible it to regularly check your heartbeat for any irregularities. If it’s consistently below 60 or above 100 beats per minute, or beats with an irregular rhythm, you should go to your doctor. A diagnosis of atrial fibrillation can be confirmed by an electrocardiogram (ECG), a test which measures the heart’s beat using electrodes.
The treatment for atrial fibrillation can include rhythm or rate control, to get the heartbeat under control, ablation to stop the abnormal electrical impulses in the heart which cause the illness, and anticoagulants to prevent the blood from clotting, reducing the risk of stroke. Your doctor will examine your particular case and circumstances to decide on the best course of treatment.
People Who’s atrial fibrillation platform has been launched to give people affected by the illness in any way – whether patients or carers – a space to meet others and find trustworthy information about the illness. At www.peoplewho.co.uk/atrialfibrillation they can find:
A Community, where users can meet others in the same situation as them, join groups of users with interests in common and follow the activities of organisations working with patients of atrial fibrillation. They can also ask questions to the community to get answers from other users and from a qualified doctor.
A Magazine with articles about treatments, prevention and new research surrounding atrial fibrillation, all supervised by doctors to ensure it’s accurate and trustworthy. Users can also submit their own stories of atrial fibrillation for publication in the magazine to share what they’ve learned, and read the stories of other users.
And a Control section where patients can keep a record of the food they eat, medication they take and any readings or test results, using this information to keep track of the illness’s progress. They can also produce reports which they can take to their doctor to give them a better idea of the patient’s life outside the surgery and to personalise their treatment.
To launch the platform, People Who have created a short informative video about how the heart works, and how atrial fibrillation is caused. To watch this video and find further information on atrial fibrillation, visit: www.peoplewho.co.uk/atrialfibrillation
Reference: [1]American Heart Association (2013), Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study
Press Contact:
Charlayne Iwanczuk – Jaime Domingo | press@peoplewho.co.uk | +44 (0) 207 193 7986
About People Who: People Who is an online platform dedicated to the everyday lives of people who live with an illness. A place for patients, carers and healthcare organisations. Together, we want to build a society which lives a little better with illness. We’re already online in France, Germany, the UK, Spain and Italy. And soon we’ll be live in the USA, Mexico, Argentina, Colombia, Peru y Chile.
ore information about the product: www.peoplewho.com
More information about the business: www.peoplewhoglobal.com
About Daiichi Sankyo: Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 17,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to its strong portfolio of medicines for hypertension, dyslipidaemia, bacterial infections, and thrombotic disorders, the Group’s research and development is focused on bringing forth novel therapies in cardiovascular-metabolic diseases, pain management, and oncology, including biologics. For more information, please visit: www.daiichisankyo.com.
Source: RealWire
The surprisingly positive treatment outcomes using Rigvir virotherapy for late stages cancer patients were recently published. The patients of melanoma stage IV M1c, small cell lung cancer stage IIIA and histiocytic sarcoma stage IV started virotherapy with Rigvir within a few months after being diagnosed and are continuing this treatment. Patients have significantly exceeded the life expectancy, which is usual for such diagnoses. After beginning the therapy their condition stabilized and the quality of life significantly improved.
Despite research and progress in melanoma therapy, mortality rates are high and melanoma is one of the common cancers in the Western world. Small lung cancer is one of the most aggressive lung cancer subtypes. Even though its response to chemotherapy and radiation is high, recurrence is common and long term survival does not exceed 5%. Histiocytic sarcoma is a rare kind of cancer and only a limited number of histiocytic sarcoma cases have been described. Using current standard treatments, the survival of patients with present diagnoses is low.
In contrast, the cancer patients described were diagnosed 3.5, 7 and 6.6 years ago and their conditions have improved and have been stable for over 1.5, 6.5 and 4 years, respectively. They have been long-term treated with Rigvir oncolytic virotherapy starting from 1 to 2 months after diagnosis. These observations suggest that oncolytic virotherapy using Rigvir can successfully be used in long-term treatment of patients with melanoma stage IV M1c, small cell lung cancer stage IIIA, and histiocytic sarcoma stage IV.
Oncolytic virotherapy with Rigvir is an active immunotherapy in cancer treatment using a virus that finds and destroys malignant cells in the human body. The world’s first approved cancer virotherapy medicine is Rigvir. It has been registered for melanoma treatment in Latvia since 2004 where approximately 75% of melanoma patients are treated with this medicine. Also it is included in national clinical guidelines for skin melanoma treatment. However in clinical practice it has also been used for treatment of several other cancers, for example, gastric and rectal cancers, where 5-year survival was improved. Rigvir has been shown to significantly reduce the mortality in melanoma stage IB-IIC patients. A retrospective study published by Melanoma Research suggests that a significant number of melanoma patients would benefit from prolonging the survival with oncolytic virotherapy treatment, moreover this can be achieved without serious side effects. Recently European Commission awarded Rigvir with a grant for cancer virotherapy medicine commercialization in the EU markets within a framework of Horizon 2020 programme “Dedicated support to the biotechnology SMEs closing the gap from lab to market”.
Source: RealWire
Fitness and wellness device users can now track their health, locate healthcare specialists and store securely, safely access and share medical history from their mobile device
Oxfordshire, 17th August 2016 – Medelinked is now integrated with Microsoft Health and Band. The integration ensures that wellness summary data from Microsoft Health app and Band wearable is available in Medelinked to help users manage their own and their family’s health.
Microsoft Health and Band enable users to collect and view their data about step counts, workouts, and even sleep quality in the mobile app and web dashboard. Vivid, easily-understandable charts help users get to know their current fitness level, and discover changes at a glance.
Integration with Medelinked also provides peace of mind that if they need urgent medical treatment at home or abroad, their secure medical history can be quickly and safely accessed and shared from their iOS or Android mobile device.
Record, connect and share
Managing all health data in one place helps individuals securely track, monitor and improve their health state, ensuring their latest health data is accessed and enabling the provision of the best possible care, keeping individuals in control of their own health. It also provides a scalable platform for device manufacturers to add value to their offerings, increase their range of services and deepen customer engagement.
Microsoft Health and Band joins other Medelinked integrated services such as Garmin Connect, UP by Jawbone, Samsung S Health, Nokia/Withings and iHealth, in enabling users to record data directly into their Medelinked health record but also include a range of medical details including allergies, conditions, immunisations, medications and tests and the ability to store clinical standard DICOM MRI scans and x-rays to complete their health profile as well as storing insurance and other documentation.
Using Medelinked individuals are also able to create personal and family health profiles online that are secure, locate healthcare specialists and connect and share their health records with their network of trusted health partners and providers (including doctors, dentists, physiotherapists, trainers, insurers, clinical researchers).
Medelinked Secure Cloud
Patients’ medical records are held securely using the Medelinked Health Cloud system. The user has sole control over the information that is stored and whether they wish any healthcare individual or organisation to view any part of their medical history.
The user can also choose any information they would like to store in a password-protected Emergency Records area, which a chosen family member or colleague can immediately access in the event of an emergency.
Ian Gallifant, Medelinked founder and CEO, says: "We are now seeing a dramatic shift in healthcare - individuals have a heightened interest in their own wellbeing and are increasingly interacting with personal technology to manage their lives.
Making a difference starts with such health information being stored in an easily accessible way and providing users with the ability to add to their records and share information easily with the healthcare professionals they locate and choose - to ensure the best advice is given based on previous history, wherever they are around the world.
Adding Microsoft Health and Band to the host of apps, sensors and devices that integrate with Medelinked ensures customers are in control of their health and personal, portable electronic health records are the way forward for improved healthcare and better outcomes in the future.”
About Microsoft Health and Band
Microsoft Health helps you live healthier by giving you actionable insights into how your physical activity benefits your overall health. View your data and insights about your step counts, workouts and even sleep quality in a mobile app and a web dashboard. Easy-to-understand graphs chart data that are important to help you understand your current, and changing, fitness levels.
Built in the cloud, Microsoft Health continuously evolves to offer you more valuable data over time. As you view your activity data, Microsoft Health helps identify opportunities to meet your goals through observations of your fitness levels. As your fitness levels and goals change, insights change with you.
Sync your Microsoft Health data with apps like MyFitnessPal, Strava, RunKeeper and MapMyFitness. Be inspired by curated workouts from Gold’s Gym, Shape and Men’s Fitness. As the number of partnerships grow, the easier it will be to manage your health and meet your wellness goals.
Using Microsoft Band gets you full access to the power of Microsoft Health, Microsoft Band tracks your heart rate, steps, calorie burn, workouts and sleep quality with eleven advanced sensors. Using your Microsoft Band data, Microsoft Health gives you access to easily-understandable summaries and charts of your health and fitness gains over time, as well as personal, valuable insights. Microsoft Band works across platforms on your Android, iPhone and Windows Phone.
Microsoft Health and Band availability
Microsoft Band works with Windows Phone 8.1 update, iOS 7.1 or later, and Android 4.3-5.0 phones, with Bluetooth. Microsoft Health app required; available in English only. Microsoft Health app is available from Google Play, Apple App Store and Windows Phone Store.
About Medelinked
Leveraging mobile technology and the cloud, the Medelinked personal health record platform aims to increase health care efficiency and effectiveness and to continuously improve health outcomes.
In use in over 80 countries around the world, Medelinked ensures that an individual’s health record is secure, complete, under their control and always available at the point of care - accessible via PC, Apple Mac or any iOS or Android tablet or smartphone.
Managing all health data in one place helps individuals securely track, monitor and improve their health state, ensuring their latest health data is accessed and enabling the provision of best possible care.
Using Medelinked individuals can request appointments and connect and share their health record with their network of trusted health partners and providers (including doctors, dentists, physiotherapists, trainers, insurers, clinical researchers).
It also enables patients to communicate securely via email, voice, text, video and instant messaging with doctors and other medical professionals and enables medical professionals to securely connect and communicate with each other to get a rapid overview of their patient or client’s history - including being able to access medical reports, records, messages, x-rays and DICOM scans with automatic updating of patient records after every consultation.
Medelinked Health Cloud and API is the leading platform already powering some of the best mHealth applications allowing developers to create a series of new applications that deliver real health benefits to the end user and healthcare professionals.
In providing this free service to patients, professionals and developers, Medelinked is building the world’s largest aggregated medical data platform for partner health solution development and research, a resource that promises to benefit patients and professionals alike as they seek to understand disease better and continuously improve outcomes.
Based in Oxfordshire, United Kingdom, Medelinked was founded in 2005 and named as one of the Global Digital Health 100 for 2015.
For more information, please visit www.medelinked.com
Further Information
Ian Gallifant
07879 994944
iangallifant@medelinked.com
Jonathan Simnett
07976 227224
jonathan.simnett@medelinked.com
Source: RealWire
1 September 2016: Micrima, the Bristol-based breast imaging company and developer of a ground-breaking and CE Mark approved radiowave breast imaging system, has successfully closed on a new financing round of £2.6m. The new funding will support accelerated development of its patented MARIA technology, which aims to enable breast screening to become safer, more comfortable and more accessible to a larger proportion of the global female population. The company intends to start the commercialisation of its first system towards the end of this year.
“Breast cancer is the most common cause of death in women between the ages of 35 and 55 in Europe and the leading cause of death for women in many countries. The problem is that many tumours are not discovered early enough, largely due to the difficulty in discriminating between cancers and dense tissue using current imaging technology,” said Roy Johnson, Micrima’s Executive Chairman. “Using harmless radiowaves, the MARIA imaging system is capable of detecting tumours in dense tissue and allows routine and repeated scanning without any of the safety or comfort concerns associated with x-ray mammography. The process takes less than five minutes and avoids painful breast compression.”
Almost half of the new funds has come from pre-existing institutional and individual investors with the majority of the balance from new high net worth individuals; 50% of the latter through the Venture Founders platform. Re-investing shareholders include Technology Venture Partners LLP, based at the Innovation Centre at Bristol & Bath Science Park, Swarraton Partners, a UK venture capital firm investing in European early stage technology companies and the British Business Bank supported Angel CoFund. The company welcomes the Parkwalk managed University of Bristol Enterprise Fund as a new investor.
The funding comes at an exciting period of significant progress for Micrima with the first clinical data from MARIA presented at the European Congress of Radiology in Vienna earlier this year to a very positive reception. The latest results from current multi-site clinical trials were presented at Symposium Mammographicum in Liverpool in July where, from over 90 papers accepted, Micrima’s was one of only four to receive an award from the organising committee. A paper reporting the pre-CE Mark clinical trial has also been accepted for publication by the prestigious Journal of Medical Imaging.
Regarding the European Congress of Radiology presentation, Dr Mike Shere of the Bristol Breast Care Centre commented, “I was delighted to be able to present the latest sensitivity figures in Vienna. The presentation on MARIA was very well received, with the chair of the breast imaging session singling the work out and commenting on how he expected to see more about this very promising new modality over the coming years."
The Company also continues to make excellent progress on the next version of the MARIA system, due to be released early next year, which will offer significantly enhanced functionality, including the ability to automatically distinguish between different types of lesion, providing a significant advantage over current methods for its future screening applications.
Tim Mills, Investment Director at the Angel CoFund commented: "We originally invested in Micrima because we knew we'd found an extremely capable team working with some very interesting technology in a sector with considerable opportunity for innovation. The team has really delivered on our expectation in the last couple of years and we're very happy to be supporting them again through this next phase of development."
The MARIA radiowave breast imaging technology was initially pioneered at the University of Bristol in the UK. It received European regulatory approval in 2015 and is currently deployed in clinical trials based at several breast cancer imaging centres throughout the UK. For more information, please visit: http://www.micrima.com or contact Roy Johnson on 07769 883882.
For editorial enquiries or photography, please contact Debbie Jones or Peter Rennison at PRPR, debbie@prpr.co.uk / pr@prpr.co.uk + 44 (0)1442 245030
About Technology Venture Partners
Technology Venture Partners is a venture capital firm based at the Bristol and Bath Science Park and investing in emerging technology companies in the South of the UK. TVP invests across a broad range of technology sectors including enterprise and infrastructure software, communications and networking, electronics, advanced engineering and materials, medical technology and healthcare IT. A number of the TVP portfolio companies were originally spinouts from leading universities and research institutions located in the South of the UK. www.techvp.co.uk
About the Angel CoFund
Launched in 2011, the Angel CoFund is a privately run fund that works alongside groups of business angels to invest in high potential SMEs across the UK. Backed by the British Business Bank and the Government’s Regional Growth Fund, the £100m Angel CoFund has already supported over 65 companies (for example Ebury, Gousto, Crowd Vision and Hopster) providing over £32 million in direct investment alongside more than £100m from business angels and other investors making it the most active early stage fund in the country. www.angelcofund.co.uk
About the University of Bristol Enterprise Fund
Launched in conjunction with the University of Bristol Research and Enterprise Development Division, the University of Bristol Enterprise Fund offer alumni and investors the opportunity to invest in the development of scientific and technological innovations from the University of Bristol and from companies supported by its world renowned SETsquared Bristol Business Incubator in a tax efficient manner. http://www.bristol.ac.uk/red/
About Swarraton Partners
Swarraton Partners LLP is a full service venture capital firm specialising in investments in early stage and growth stage small companies. The firm invests in companies commercialising technology in sectors such as energy and resources technology, nano and materials technology and medical innovation. http://www.swarraton.com/
Source: RealWire
Fitness and wellness device users can now track their health, locate healthcare specialists and store securely, safely access and share medical history from their mobile device
Oxfordshire, 8th September 2016 – Medelinked is now integrated with Omron Healthcare Blood Pressure Monitors and Alvita Activity Trackers and Pedometers.* The integration with devices from the heart health and wellness technology market leader ensures that wellness summary data from Omron devices is available in Medelinked to help users better manage their own and their family’s health.
Omron blood pressure monitors are recognised and certified as some of the most accurate available to consumers and are the number one home blood pressure monitor recommended by doctors and pharmacists.
Alvita provides wireless, light-weight and optimised devices that allow users to place them in their pockets or on their body and feel assured that they will accurately track all of their steps towards a healthier lifestyle.
Record, connect and share
Integration with Medelinked provides peace of mind that if Omron device users need urgent medical treatment at home or abroad, their secure medical history can be quickly and safely accessed and shared from their iOS or Android mobile device.
Managing all health data in one place helps individuals securely track, monitor and improve their health state, ensuring their latest health data is accessed and enabling the provision of the best possible care, keeping individuals in control of their own health. It also provides a scalable platform for device manufacturers to add value to their offerings, increase their range of services and deepen customer engagement.
Joins a wide range of other Medelinked integrated devices and services
The Omron devices join a wide range of other Medelinked integrated devices and services such as Microsoft Health and Band, Garmin Connect, UP by Jawbone, Samsung S Health, Nokia/Withings and iHealth, in enabling users to record data directly into their Medelinked health record. Medelinked also enables the inclusion of a range of medical details including allergies, conditions, immunisations, medications and tests and the ability to store clinical standard DICOM MRI scans and x-rays to complete their health profile as well as storing insurance and other documentation.
Using Medelinked, individuals are also able to create personal and family health profiles online that are secure, locate healthcare specialists and connect and share their health records with their network of trusted health partners and providers (including doctors, dentists, physiotherapists, trainers, insurers, clinical researchers).
Medelinked Secure Cloud
Patients’ medical records are held securely using the Medelinked Health Cloud system. The user has sole control over the information that is stored and whether they wish any healthcare individual or organisation to view any part of their medical history.
The user can also choose any information they would like to store in a password-protected Emergency Records area, which a chosen family member or colleague can immediately access in the event of an emergency.
Dramatic shift in healthcare
Ian Gallifant, Medelinked founder and CEO, says: "We are now seeing a dramatic shift in healthcare - individuals have a heightened interest in their own wellbeing and are increasingly interacting with personal technology to manage their lives.
Making a difference starts with such health information being stored in an easily accessible way and providing users with the ability to add to their records and share information easily with the healthcare professionals they locate and choose - to ensure the best advice is given based on previous history, wherever they are around the world.
Adding Omron blood pressure monitors, activity trackers and pedometers to the host of apps, sensors and devices that integrate with Medelinked ensures customers are in control of their health and that personal, portable electronic health records are the way forward for improved healthcare and better outcomes in the future.”
*Medelinked is integrated with the following Omron devices: Blood Pressure Monitors - Upper Arm: Omron 7 Series plus Bluetooth Smart (BP761/BP761N) & Omron 10 Series plus Bluetooth Smart (BP786/BP786N). Wrist: Omron 7 Series plus Bluetooth Smart (BP654) & Omron 10 Series plus Bluetooth Smart (BP653). Omron Alvita Wireless Activity Tracker (HJ-327T) and Alvita USB Pedometer (HJ-323U/HJ-322U/HJ-324U)
About Omron Healthcare, Inc.
Omron Healthcare, Inc. is a leading manufacturer and distributor of personal wellness products. Omron’s market-leading products include home blood pressure monitors and electrotherapy devices.
Since Omron invented its first blood pressure monitors more than 40 years ago, the company has been passionate about empowering people to take charge of their health at home through precise technology. Helping people improve their ability to live a healthier life is the heart and soul of Omron’s purpose.
For more information, visit OmronHealthcare.com.
About Medelinked
Leveraging mobile technology and the cloud, the Medelinked personal health record platform aims to increase health care efficiency and effectiveness and to continuously improve health outcomes.
In use in over 80 countries around the world, Medelinked ensures that an individual’s health record is secure, complete, under their control and always available at the point of care - accessible via PC, Apple Mac or any iOS or Android tablet or smartphone.
Managing all health data in one place helps individuals securely track, monitor and improve their health state, ensuring their latest health data is accessed and enabling the provision of best possible care.
Using Medelinked individuals can request appointments and connect and share their health record with their network of trusted health partners and providers (including doctors, dentists, physiotherapists, trainers, insurers, clinical researchers).
It also enables patients to communicate securely via email, voice, text, video and instant messaging with doctors and other medical professionals and enables medical professionals to securely connect and communicate with each other to get a rapid overview of their patient or client’s history - including being able to access medical reports, records, messages, x-rays and DICOM scans with automatic updating of patient records after every consultation.
Medelinked Health Cloud and API is the leading platform already powering some of the best mHealth applications allowing developers to create a series of new applications that deliver real health benefits to the end user and healthcare professionals.
In providing this free service to patients, professionals and developers, Medelinked is building the world’s largest aggregated medical data platform for partner health solution development and research, a resource that promises to benefit patients and professionals alike as they seek to understand disease better and continuously improve outcomes.
Based in Oxfordshire, United Kingdom, Medelinked was founded in 2005 and named as one of the Global Digital Health 100 for 2015.
For more information, please visit www.medelinked.com
Further Information
Ian Gallifant
07879 994944
iangallifant@medelinked.com
Jonathan Simnett
07976 227224
jonathan.simnett@medelinked.com
Source: RealWire
Developers of the MIA Maternity app are taking a step for every baby in need of specialist care in the UK.
The Isosec Charity of the Year 2016 is Bliss. Bliss exists to ensure that every baby born premature or sick in the UK has the best chance of survival and quality of life.
Every year, 90,000 babies are admitted to a hospital for specialist care – many of these babies will need lifesaving intensive care. Bliss is there for these little ones by empowering their families and working with health professionals to ensure they have the best care possible.
Isosec have developed the MIA Maternity app for Midwives in the NHS. MIA Maternity transforms paper processes into a streamlined mobile app to save clinician’s time and money to be spent on better patient care. As a result of working with Maternity departments across the country Isosec have seen first hand the difference Bliss makes to families. Special features have been built into the MIA Maternity app workflow for babies born under 37 weeks; ensuring families get the support available to them.
To support Bliss the Isosec team have committed to walk a foot for every single one of the 90,000 babies born premature in one year. That's over 17 miles, which Isosec will be trekking around the Peak District in October.
Isosec will also be holding a 90,000 step week challenge and bake sale in Manchester in November to raise further awareness and funds for Bliss. Check our website and social media for updates and more information on how to take part.
Please donate as much or as little as you can for this worthy cause and help us to help those in need. Our target is £1000 although we hope to exceed it. Isosec really appreciate your continued support and thank you in advance for any donations to our heartfelt cause.
To make a donation please visit uk.virginmoneygiving.com/Isosec.
END
EDITORS NOTE
Contact: Jo Flynn, Marketing Executive, Isosec Ltd.
Phone: 0161 376 3570
Email: jo.flynn@isosec.co.uk
Isosec are a rapidly expanding software company developing secure mobile app solutions for clinical use in the NHS. Based in Manchester, UK. For more information please visit www.isosec.co.uk.
###
Source: RealWire
Driving educational, scientific and medical cooperation for excellence in health care
15/Feb/2017 Tanzania: In an ongoing pursuit of delivering paramount medical services and health care facilities to the African nations, India (New Delhi) based BLK Super Speciality Hospital has announced signing of a Memorandum of Understanding (MoU) with Muhimbili Orthopaedic Institute (MOI), which is one of the largest orthopaedic hospitals in Tanzania. The pact would help promote cooperation and mutual understanding between the two countries.
BLK Super Speciality Hospital has been extending medical services in Tanzania in the past as well. The hospital has also signed a similar pact with The Jakaya Kikwete Cardiac Institute (JKCI) in 2015. Doctors from BLK Super Speciality Hospital have been regularly visiting Tanzania offering multiple speciality care and services along with surgical interventions in the region.
This strategic partnership with MOI will ensure quality medical consultation and management of the patients for specialised services. Talking on the pact with MOI, Mr. Naresh Kapoor, Executive Director, BLK Super Speciality Hospital, said, “We are happy to extend medical support in different parts of the world and with this partnership, we shall assist MOI achieve its objective of becoming a preferred and advanced healthcare destination for the people of Tanzania and the East African region by knowledge sharing, transfer of skills and capacity building. The pact will also allow our doctors and technical experts, to periodically visit and train MOI’s medical staff keeping them abreast with the latest developments in medical sciences.”
“This partnership aims to set up a platform for both the hospitals enabling each to share their experiences and expertise. The two institutions in particular will develop educational, scientific and medical cooperation through surgical camps, workshops, observerships and Continuing Medical Education (CME) programmes” added Mr Kapoor.
Dr. Othman, Executive Director, Muhimbili Orthopaedic Institute, said, “It is a matter of privilege for us to collaborate with BLK Super Speciality Hospital, which is one of the largest hospitals in Delhi NCR with 650 beds. This pact shall give us opportunities to develop and establish our institute as the leading and advanced healthcare destination for our people. The MoU shall also pave the way for strengthening our pre and post-operative patients care through exchange programs. We see this as a great opportunity to learn from each other’s strengths and is a progressive step forward for cultural exchange.”
Senior and eminent doctors like Dr. Puneet Giridhar, Director - Spine Surgery, BLK Centre for Orthopaedics and Spine Surgery and Dr Subhash Chandra, Chairman & HoD, Cardiology, BLK Heart Centre from BLK Super Speciality Hospital will visit Tanzania from 13th to 15th February. During their visit they will perform Orthopaedic and Cardiac surgical interventions. Dr Puneet Girdhar will perform interventions like lumbar discectomy, cervical discectomy, thoracolumbar spinal fixation, disc replacement and spinal stabilization or fusion surgery at MOI, while Dr. Subhash Chandra will perform various cardiac procedures including Peripheral Angioplasties, Coronary Angioplasties and Balloon Mitral Valvoplasties or Valvotomies at JKCI.
About BLK Super Speciality Hospital
BLK Super Speciality is one of the largest private hospitals in the National Capital Region (NCR) of Delhi with a capacity of 650 beds including 140 critical care beds. The outpatient services are spread over two floors with 57 consultation rooms. All ambulatory services are smartly designed to ensure quick access to interventional services. The Hospital has 17 state-of-the-art well equipped modular operation theaters and a world-class pathology lab. The Hospital is equipped with most modern infrastructure, and eminent doctors drive its Centers of Excellence. The hospital has Asia’s largest Bone Marrow Transplant Units. We have deployed very high-end technologies such as Cyberknife VSI, TriologyTxLinear Accelerator, Bi Plane Neuro Interventional lab which are geared to address complex medical needs of patients. Our infrastructure and services stand testimony to BLK’s philosophy of A Passion for Healing. The hospital is owned and managed by Radiant Life Care, which also manages Mumbai’s iconic Nanavati Super Speciality Hospital.
For more information please contact:
Seema Choudhary
seema@mediavalueworks.com
+91 869 289 2550
Source: RealWire